- Articles by Topic
- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & Rapid Micro Methods (RMMs)
- Process Analytical Technology (PAT) & Quality by Design (QbD)
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Latest News
- Contact us
The latest news from the pharmaceutical industry and suppliers. If you have a piece of news that you would like us to cover, please contact Caroline Richards on +44 (0)1959 563311 or email us.
Posted on: 26 February 2015 | Source: GAFFI
Early detection and treatment of fungal meningitis and pneumonia can save hundreds of thousands of lives, for a cost of 'only $30' per HIV patient, the world's first stakeholder meeting on fungal diseases hosted by GAFFI (Global Action Fund for Fungal Infections) and held in Seattle, USA has concluded...
48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation
Posted on: 26 February 2015 | Source: Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients...
Posted on: 26 February 2015 | Source: GlobalData
The global market for atrial fibrillation (AF) treatment will more than double in value from $4.6 billion in 2013 to peak sales of $9.4 billion in 2020, before declining to $5.7 billion by 2023 as new oral anticoagulants (NOACs) become genericized, according to research and consulting firm GlobalData...
Posted on: 26 February 2015 | Source: Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...
Launch of Turing Pharmaceuticals announced – new drug company to focus on treating unmet medical needs across broad therapeutic areas
Posted on: 25 February 2015 | Source: Turing Pharmaceuticals
Turing launches with three major product acquisitions: intranasal ketamine program, Syntocinon® Nasal Spray, and Vecamyl®; company introduces senior leadership team...
Posted on: 25 February 2015 | Source: Medical Research Council
Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England...
Posted on: 25 February 2015 | Source: Ipsen / Canbex Therapeutics Ltd
Ipsen and Canbex Therapeutics Ltd announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R...
Posted on: 25 February 2015 | Source: British Generic Manufacturers Association
Competition will allow more patients to be treated at lower cost...
Prize winning diabetes initiatives demonstrate both improved patient outcomes and cost savings to the NHS
Posted on: 24 February 2015 | Source: Janssen
2015 NHS Innovation Challenge prize winners announced...
Posted on: 24 February 2015 | Source: UCB
UCB announced that the company’s newly appointed Chief Executive Officer, Jean-Christophe Tellier, has been selected to join the Ministerial Industry Strategy Group...
Posted on: 24 February 2015 | Source: GBI Research
While drug candidates for Alzheimer’s Disease fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research...
Posted on: 24 February 2015 | Source: Kuros
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947...
ABB Analytical Measurement Analytik Jena AG B&W Tek, Inc. CAMO Software AS Coulter Partners EUROGENTEC GE Analytical Instruments Hyglos GmbH IDBS IONICON Analytik GmbH Natoli Engineering Company, Inc. ReAgent Thermo Fisher Scientific Waters Corporation